Published in Blood Weekly, January 29th, 2004
A total of 9.775 million shares were issued and net proceeds after expenses from this transaction generated approximately $92 million.
Approximately $20 million of proceeds will be used to develop or acquire internal commercial manufacturing capacity for StaphVAX, the company's lead product in development for preventing Staphylococcus aureus blood stream infections, and $9.5 million will be used to repay a term loan under the company's existing credit agreement. Additional planned uses of proceeds include support for future clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.